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Introduction: The ﬁstulizing form of Crohn’s disease (CD) represents a great challenge
regarding  treatment, especially perianal ﬁstulas, for its high prevalence.
Objective:  To assess factors related to the response to surgical treatment associated with
anti-TNF  inpatients with CD and perianal ﬁstulas.
Method: Retrospective study of patients with CD and perianal ﬁstulas who used IFX or ADA
in  association with surgical treatment.
Results: 30 patients with a mean age of 35 years were studied; 16 were treated with ADA (9
ADA  + AZA) and 14 with IFX (10 IFX + AZA); ten of those treated with ADA responded, and
of  the six non-respondents, only one responded to IFX; eight responded to IFX, and among
those  non-respondents, no one showed response with ADA; among the respondents, there
were  10 men and nine women; of those non-respondents, eight were  men  and 3 women;
of  those under 40 years, 16 responded compared with only three non-respondents; of those
over  40 years, three responded versus eight non-respondents; as to the time elapsed between
the  onset of the disease and the beginning of anti-TNF, 14 (<2 years), one (2–5 years) and
four  (>5 years) responded, and ﬁve (<2 years), four (2–5 years) and two (>5 years) were  non-
respondents.
Conclusion:  There was no difference in response between the anti-TNF agents used; a better
response was noted in those who used anti-TNF in combination with azathioprine, among
women, in those under 40 years and in those treated within two years of the onset of the
disease.
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Comparac¸ão  entre  Adalimumabe  e  Inﬂiximabe  no  tratamento  das  fístulas
perianais  na  Doenc¸a  de  Crohn
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Introduc¸ão: A forma ﬁstulizante da Doenc¸a  de Crohn (DC) apresenta um grande desaﬁo
quanto ao seu tratamento, especialmente as fístulas perianais pela sua alta prevalência.
Objetivo: Analisar os fatores relacionados à resposta ao tratamento cirúrgico associado ao
anti-TNF de pacientes com fístulas perianais por DC.
Método: Estudo retrospectivo de pacientes com fístulas perianais por DC que ﬁzeram uso de
IFX ou ADA associado ao tratamento cirúrgico.
Resultados: Foram estudados 30 pacientes com média de idade de 35 anos; 16 foram tratados
com ADA (9 ADA + AZA) e 14 com IFX (10 IFX + AZA); 10 dos tratados com ADA tiveram
resposta; e dos seis que não responderam, apenas um teve resposta com IFX; oito tiveram
resposta com IFX; e dos que não responderam, nenhum apresentou resposta com ADA; dos
que responderam, 10 eram homens e nove mulheres; dos que não responderam, oito eram
homens e três mulheres; daqueles com menos de 40 anos, 16 responderam contra apenas
três que não responderam; dos com mais de 40 anos, três responderam contra oito que não
responderam; quanto ao tempo decorrido entre o início da doenc¸a  e o início do anti-TNF,
14 (<2 anos), um (2-5 anos) e quatro (>5 anos) responderam, e cinco (<2 anos), quatro (2-5
anos) e dois (>5 anos) não responderam.
Conclusão:  Não houve diferenc¸a  de resposta entre os agentes anti-TNF utilizados; houve
melhor resposta nos que utilizaram anti-TNF em associac¸ão  com azatioprina, entre as
mulheres, nos pacientes com menos de 40 anos e naqueles tratados com até dois anos
do início da doenc¸a.
©  2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
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n itself, Crohn’s disease (CD) constitutes a major challenge
or  the physician treating inﬂammatory bowel diseases. Those
ases  with ﬁstulizing disease, particularly perianal ﬁstulas,
ecome  even more  challenging, as there is great difﬁculty in
chieving its control in the long-term, even with the therapeu-
ic  advances made in recent years.1
Today we  know that the best therapeutic option for this
resentation of CD is the association of surgical treatment
ith  the use of anti-TNF agents, and in this sense, “surgi-
al  treatment” is not the classic ﬁstulotomy or ﬁstulectomy,
ut  successive curettages and seton placements, allowing that
he  biologicals act in the healing process without formation of
bscesses.2
The conventional treatment of perianal ﬁstulas in patients
ithout  CD produces excellent results; but in patients with
D  one cannot employ the usual techniques in most cases,
iven  the high probability of developing fecal incontinence.
his situation changed positively with the emergence of bio-
ogical  agents, which signiﬁcantly changed the treatment of
his  disease.
At  the beginning of the use of biological agents, an increase
n  the incidence of perianal abscesses was  also noted (because
f  the external oriﬁce closure by the drug), but over time it was
ound  that the combination of biologicals with frequent curet-
age  of ﬁstulas and seton placement constituted an effective
trategy,  having become the standard treatment for perianal
stulas  in patients with CD.3What is being discussed today, in face of the inexistence
of clear scientiﬁc evidence, is whether there are differences
between the available biologicals, especially adalimumab and
inﬂiximab,  which are the most used in Brazil. Thus, the aim
of  this study is to compare these two agents as to the differ-
ences  in response to treatment with anti-TNF associated with
surgical  treatment in CD patients with perianal ﬁstulas.
Objective
To assess factors related to the response to surgical treat-
ment  associated with anti-TNF (adalimumab and inﬂiximab)
of  patients with perianal ﬁstulas in Crohn’s disease.
Method
A retrospective study of medical records of patients from the
Inﬂammatory Bowel Diseases Outpatient Clinic, Hospital Uni-
versitario  Maria Aparecida Pedrossian, Universidade Federal
de  Mato Grosso do Sul, from the Hospital Regional de Mato
Grosso  do Sul, and from the private practice of the author.
Patients  with perianal ﬁstulas and Crohn’s disease with
prescription and who made use of anti-TNF agents were
included. All patients included were previously investigated
for  presence of TB and Hepatitis B.The study period was  from June 2000 to July 2013. Anti-
TNF  agents were used at recommended doses and intervals:
inﬂiximab (IFX) 5 mg/kg at weeks 0, 2 and 6 with maintenance
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Fig. 2 – Comparison between patients treated with
inﬂiximab and adalimumab, combined or not with
lost response. In the group treated with anti-TNF more  than
ﬁve  years after diagnosis, four showed no response versus two
respondents (Fig. 5).
WomenMen
10.0
7.5
5.0
2.5
0the  patient.
every 8 weeks, and adalimumab (ADA) 160 mg  at week 0, 80 mg
at week 2 and then 40 mg  every 2 weeks.
All  patients were  treated by curettage and seton placement,
with  successive changes if necessary, until there was  the pos-
sibility  of removing the lesion. On average, the beginning of
the  biological therapy occurred one week after surgery.
Absence of pain and discharge for more  than six months
was  considered as a satisfactory response to treatment.
The  results were  statistically analyzed by Student’s t test
and  chi-squared test, and P < 0.05 was  considered statistically
signiﬁcant.
Results
30 patients (18 male and 12 female) were  studied. The age
ranged  from 16 to 58 years, with a mean of 35 years.
The choice of an anti-TNF agent was  based on the availabil-
ity  and preference of patients, similarly to the data from the
literature  on the subject.4,5 Of the 30 patients, 16 were treated
with  adalimumab and 14 with inﬂiximab (Fig. 1).
The  period of use of these anti-TNF agents ranged from 3
to  30 months, with a mean of 18 months.
Of those 16 patients using ADA, nine were also treated with
azathioprine (AZA), while of those 14 who were treated with
IFX,  10 also used AZA.
In  the group treated with ADA, 10 had response and con-
tinued  their treatment. Of the six non-respondents, three
stopped  its use altogether and three others started using IFX.
Of  these, only one had a response, remaining on this medica-
tion.  In the group treated with IFX, eight responded. Of those
six  non-respondents, one stopped using anti-TNF and the
other  ﬁve started using ADA. Of these, no one had a response
and  the anti-TNF treatment was  discontinued (Fig. 2).
There  was  no difference in our results when comparing
anti-TNF agents (P = 0.22). However, it became evident that
the  combination of anti-TNF with AZA was  superior versus
monotherapy with this agent (P = 0.01).
When  analyzing the results according to gender, it was
observed that 10 men  versus nine women (P = 0.13) responded,
whereas  eight men  versus three women  (P = 0.03) failed to
respond  (Fig. 3).
When  the results of treatment of perianal ﬁstulas accord-
ing  to age were  analyzed, we  observed that younger patients
had  better response versus older participants (P = 0.00002). Ofazathioprine, in CD patients with perianal ﬁstula.
those aged less than 40 years, 16 responded versus three non-
respondents,  while in those aged more  than 40 years, only
three  responded versus eight non-respondents (Fig. 4).
In  the analysis of the response to treatment with anti-TNF
in  relation to the time elapsed between the diagnosis of peri-
anal  ﬁstula in CD patients and the beginning of the therapy
with  the biological agent, it was  found that 19 patients started
anti-TNF  therapy before two years of disease, ﬁve patients
between two and ﬁve years, and six patients after more  than
ﬁve  years of diagnosis.
Of  those who started the treatment within two years of
diagnosis, 14 responded versus ﬁve non-respondents/with lost
response. Of those treated from two to ﬁve years of diagnosis,
only  one responded, while four were non-respondents/withNon-respondentsRespondents
Fig. 3 – Comparison between genders as to response to
anti-TNF  therapy in patients with CD and perianal ﬁstula.
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iscussion
 recent Brazilian publication on the epidemiology of CD
howed  that half of patients treated with the biological agent
resented  perianal disease, mainly perianal ﬁstulas, high-
ighting  the importance of this form of the disease and the
eed  for an effective treatment.1
In a study of great relevance on this subject, Sands et al.6
bserved that only 36% of their CD patients with ﬁstulas main-
ained  response after 54 weeks of IFX use. This demonstrates
hat, despite the great contribution given by the biologicals to
he treatment of CD, particularly in the ﬁstulizing variety, the
ajority  of patients still do not achieve a satisfactory response
ith  this therapy. Although the design of this article does not
llow  a direct comparison with the Sands et al. paper,6 we
bserved  a complete response in 60% of cases.
Those individuals who show a good initial response to bio-
ogicals  usually keep it over time.7 This fact was also observed
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ig. 5 – Evaluation of response to anti-TNF therapy in CD
atients  with perianal ﬁstula in time elapsed between
iagnosis and the use of a biological agent.
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in the present study. The CHARM study also showed efﬁcacy
of  ADA in 33% of cases of perianal ﬁstulas at week 56, a ﬁnding
very  similar to that presented in the study of Sands et al.
Although  the CHOICE study has shown encouraging results
regarding  the use of ADA in patients that failed with IFX, the
same  could not be observed in the present study. Lichtiger
et  al. observed that 39% of patients who  had failed with
IFX  were successful in the healing of perianal ﬁstulas and
improved  their quality of life. In our study, only one non-
respondent patient with ADA was  successful with IFX.8
There are many  publications on this subject, several of
them  of great consequence, but there is a shortage of articles
evaluating other factors involved in the response to biologi-
cal  agents in CD patients with perianal ﬁstulas. It seemed to
us  quite interesting to note that women had less treatment
failures versus men  with the use of biologicals. In the medical
literature, there is little information on this subject.
In  the present study we  observed a better response in the
younger  group of patients, but there is no similar evidence in
the literature. Weiss et al.9 found no difference in response to
treatment with anti-TNF as to the age of patients in a recently
published study, in which these authors analyzed this variable
in  relation to age group.
Currently,  the time elapsed between the onset of symptoms
of  CD and the treatment with anti-TNF has been valued, since
the  shorter this time, the better the response to the therapy.10
The same phenomenon was  observed in the present study,
given  that the group treated at less than two years of diag-
nosis  obtained better results than those treated within the
period  between two and ﬁve years. And this second group
obtained better results than the group treated after ﬁve years
of  diagnosis.
Conclusion
There was no difference in response between anti-TNF agents
used;  there was  a better response for those who used anti-
TNF  in combination with azathioprine, among women, in the
group  under 40 years and in those treated within two years of
onset  of the disease.
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